Skip to main content

Table 1 Patient demographics and clinicopathological characteristics for Stage I, II, III patients with HER2-positive breast cancer

From: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

At time of diagnosis of index cancer

    

Variable

N (%)

Total

(N = 3394)

HR-positive

(n = 2015)

HR-negative

(n = 1379)

P-value

Age, mean (se), y

52.48 (0.21)

52.41 (0.29)

52.59 (0.32)

 

Age category, N, (%)

   

<.001

0 to <50

1,514 (45)

931 (46)

583 (42)

 

50 to <70

1,547 (46)

865 (43)

682 (49)

 

70+

333 (10)

219 (11)

114 (8)

 

Race/Ethnicity, N, (%)

   

0.030

African-American

259 (8)

135 (7)

124 (9)

 

Caucasian

2,693 (79)

1,627 (81)

1,066 (77)

 

Hispanic

262 (8)

155 (8)

107 (8)

 

Asian Pacific Island

126 (4)

64 (3)

62 (5)

 

American Indian

10 (<1)

4 (<1)

6 (<1)

 

Other

16 (<1)

10 (1)

6 (<1)

 

Unknown

28 (1)

20 (1)

8 (1)

 

Menopausal Status, N, (%)

   

0.001

Premenopausal

1,569 (46)

978 (49)

591 (43)

 

Postmenopausal

1,825 (54)

1,037 (51)

788 (57)

 

Body Mass Index kg/m2, N, (%)

   

0.512

<18.5 kg/m2 (Underweight)

52 (2)

34 (2)

18 (1)

 

18.5 to <25 kg/m2 (Normal)

1,263 (37)

750 (37)

513 (37)

 

25 to <30 kg/m2 (Obese)

913 (27)

554 (27)

359 (26)

 

>30 kg/m2 (Severely Obese)

884 (26)

506 (25)

378 (27)

 

Missing/unknown

282 (8)

171 (8)

111 (8)

 

Co-morbidity score, N, (%)

   

0.958

0

2,713 (80)

1,609 (80)

1,104 (80)

 

1

452 (13)

271 (13)

181 (13)

 

2+

229 (7)

135 (7)

94 (7)

 

Method of detection, N, (%)

   

<.001

Abnormal screening mammogram

1,209 (36)

755 (37)

454 (33)

 

Symptom

2,012 (59)

1,175 (58)

837 (61)

 

Other

147 (4)

67 (3)

80 (6)

 

Unknown

26 (1)

18 (1)

8 (1)

 

T stage, category, N, (%)

   

<.001

T1

1,753 (52)

1,103 (55)

650 (47)

 

T2

1,150 (34)

691 (34)

459 (33)

 

T3

244 (7)

129 (6)

115 (8)

 

T4

197 (6)

73 (4)

124 (9)

 

Unknown

50 (1)

19 (1)

31 (2)

 

Nodal status, N, (%)

   

<.001

Positive

1,623 (48)

907 (45)

716 (52)

 

Negative

1,757 (52)

1,101 (55)

656 (48)

 

Unknown

14 (<1)

7 (<1)

7 (<1)

 

AJCC stage, N, (%)

   

<.001

I

1,187 (35)

772 (38)

415 (30)

 

II

1,467 (43)

887 (44)

580 (42)

 

III

740 (22)

356 (18)

384 (28)

 

Histologic grade, N, (%)

   

<.001

Low/Intermediate

907 (27)

719 (36)

188 (14)

 

High

2,324 (68)

1,211 (60)

1,113 (81)

 

Unknown

163 (5)

85 (4)

78 (6)

 

Histology, N, (%)

   

<.001

Invasive ductal

3,101 (91)

1,772 (88)

1,329 (97)

 

Invasive lobular

105 (3)

89 (4)

16 (1)

 

Mixed ductal and lobular

139 (4)

120 (6)

19 (1)

 

Other

49 (1)

34 (2)

15 (1)

 

LVI, N, (%)

   

0.630

Presence

1,164 (34)

678 (34)

486 (35)

 

Absence

2,113 (62)

1,267 (63)

846 (61)

 

Unknown

117 (3)

70 (3)

47 (3)

 

EIC, N, (%)

   

0.536

Presence

606 (18)

353 (18)

253 (18)

 

Absence

2,788 (82)

1,662 (82)

1,126 (82)

 

In patients with documented recurrence

    

Variable

Total

N = 458

HR-positive

N = 208

HR-negative

N = 250

P -value

Disease free interval median (range), y

1.95 (7.69)

2.24 (7.69)

1.70 (7.08)

 

Age, mean (se), y

50.95 (0.60)

50.39 (0.94)

51.41 (0.78)

 

Race/Ethnicity, N, (%)

   

0.644

African-American

51 (11)

21 (10)

30 (12)

 

Caucasian

358 (78)

166 (80)

192 (77)

 

Hispanic

31 (7)

12 (6)

19 (8)

 

Asian Pacific Island

12 (3)

6 (3)

6 (2)

 

American Indian

1 (<1)

1 (<1)

0 (0)

 

Other

4 (1)

1 (<1)

3 (1)

 

Unknown

1 (<1)

1 (<1)

0 (0)

 

Menopausal status at time of diagnosis of index cancer, N, (%)

   

0.207

Premenopausal

223 (49)

108 (52)

115 (46)

 

Postmenopausal

235 (51)

100 (48)

135 (54)

 

Co-morbidity score at time of diagnosis of index cancer, N, (%)

   

0.437

0

371 (81)

166 (80)

205 (82)

 

1

57 (12)

25 (12)

32 (13)

 

2+

30 (7)

17 (8)

13 (5)

 

AJCC stage at time of diagnosis of index cancer, N, (%)

   

0.437

I

77 (17)

36 (17)

41 (16)

 

II

188 (41)

91 (44)

97 (39)

 

III

193 (42)

81 (39)

112 (45)

 

Histologic grade at time of diagnosis of index cancer, N, (%)

   

0.016

Low/Intermediate

65 (14)

40 (19)

25 (10)

 

High

379 (83)

163 (79)

216 (86)

 

Unknown

14 (3)

5 (2)

9 (4)

 
  1. Note: AJCC, American Joint Committee on Cancer Staging; EIC, extensive intraductal component; HR, Hormone receptor; LVI, Lymphovascular invasion; se, standard error; y, year